Oral melphalan as a treatment for platinum-resistant ovarian cancerHASAN, J; JAYSON, G. C.British journal of cancer. 2003, Vol 88, Num 12, pp 1828-1830, issn 0007-0920, 3 p.Article

Carcinomatous meningitis in solid tumoursJAYSON, G. C; HOWELL, A.Annals of oncology. 1996, Vol 7, Num 8, pp 773-786, issn 0923-7534Article

The current and future management of malignant ascitesSMITH, E. M; JAYSON, G. C.Clinical oncology (Springer. Print). 2003, Vol 15, Num 2, pp 59-72, issn 0936-6555, 14 p.Article

Intra-tumoural microvessel density in human solid tumoursHASAN, J; BYERS, R; JAYSON, G. C et al.British journal of cancer. 2002, Vol 86, Num 10, pp 1566-1577, issn 0007-0920Article

The clinical potential of antiangiogenic fragments of extracellular matrix proteinsCLAMP, A. R; JAYSON, G. C.British journal of cancer. 2005, Vol 93, Num 9, pp 967-972, issn 0007-0920, 6 p.Article

Biomarkers of angiogenesis and their role in the development of VEGF inhibitorsMURUKESH, N; DIVE, C; JAYSON, G. C et al.British journal of cancer. 2010, Vol 102, Num 1, pp 8-18, issn 0007-0920, 11 p.Article

Heparin oligosaccharides : inhibitors of the biological activity of bFGF on Caco-2 cellsJAYSON, G. C; GALLAGHER, J. T.British journal of cancer. 1997, Vol 75, Num 1, pp 9-16, issn 0007-0920Article

Antiangiogenic drugs in ovarian cancerKUMARAN, G. C; JAYSON, G. C; CLAMP, A. R et al.British journal of cancer. 2009, Vol 100, Num 1, pp 1-7, issn 0007-0920, 7 p.Article

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, pegylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volumeJAYSON, G. C; PARKER, G. J. M; BUCKLEY, D. L et al.Journal of clinical oncology. 2005, Vol 23, Num 5, pp 973-981, issn 0732-183X, 9 p.Article

Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancyDUFF, S. E; LI, C; JEZIORSKA, M et al.British journal of cancer. 2003, Vol 89, Num 3, pp 426-430, issn 0007-0920, 5 p.Article

Metallothionein expression in epithelial ovarian cancer : effect of chemotherapy and prognostic significanceWRIGLEY, E; VERSPAGET, H. W; JAYSON, G. C et al.Journal of cancer research and clinical oncology. 2000, Vol 126, Num 12, pp 717-721, issn 0171-5216Article

A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamicsMITCHELL, Claire L; O'CONNOR, J. P. B; RUDMAN, S et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 3, pp 631-641, issn 0344-5704, 11 p.Article

Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapyMITCHELL, C. L; O'CONNOR, J. P. B; HASAN, J et al.Annals of oncology. 2010, Vol 21, Num 10, pp 1982-1989, issn 0923-7534, 8 p.Article

Heparan sulphate synthetic and editing enzymes in ovarian cancerBACKEN, A. C; COLE, C. L; LAU, S. C et al.British journal of cancer. 2007, Vol 96, Num 10, pp 1544-1548, issn 0007-0920, 5 p.Article

Quantitative angiogenesis assays in vivo: a reviewHASAN, Jurjees; SHNYDER, S. D; BIBBY, M et al.Angiogenesis (London). 2004, Vol 7, Num 1, pp 1-16, issn 0969-6970, 16 p.Article

Synthesis of [¹⁸F] fluoroacetaldehyde. Application to [¹⁸F]fluoroethylation of benzylamine under reductive alkylation conditionsPRENANT, C; GILLIES, J; BAILEY, J et al.Journal of labelled compounds & radiopharmaceuticals. 2008, Vol 51, Num 5-6, pp 262-267, issn 0362-4803, 6 p.Article

Heparan sulfate proteoglycans and cancerBLACKHALL, F. H; MERRY, C. L. R; DAVIES, E. J et al.British journal of cancer. 2001, Vol 85, Num 8, pp 1094-1098, issn 0007-0920Article

Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesotheliomaWHITE, S. C; ANDERSON, H; JAYSON, G. C et al.Annals of oncology. 2000, Vol 11, Num 2, pp 201-206, issn 0923-7534Article

p53 And related proteins in epithelial ovarian cancerSENGUPTA, P. S; MCGOWN, A. T; SLADE, R. J et al.European journal of cancer (1990). 2000, Vol 36, Num 18, pp 2317-2328, issn 0959-8049Article

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusionJAYSON, G. C; CROWTHER, D; PETTIT, G. R et al.British journal of cancer. 1995, Vol 72, Num 2, pp 461-468, issn 0007-0920Article

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumorsJONKER, D. J; ROSEN, L. S; KANTOR, J et al.Annals of oncology. 2011, Vol 22, Num 6, pp 1413-1419, issn 0923-7534, 7 p.Article

DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6O'CONNOR, J. P. B; ROSE, C. J; CLAMP, A. R et al.British journal of cancer. 2011, Vol 105, Num 1, pp 139-145, issn 0007-0920, 7 p.Article

Phase I Evaluation of CDP791, a PEGylated Di-Fab' Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2TON, N. C; PARKER, G. J. M; POWER, F et al.Clinical cancer research. 2007, Vol 13, Num 23, pp 7113-7118, issn 1078-0432, 6 p.Article

Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculatureSHNYDER, S. D; HASAN, J; COOPER, P. A et al.Anticancer research. 2005, Vol 25, Num 3B, pp 1889-1894, issn 0250-7005, 6 p.Article

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancerHASAN, J; TON, N; MULLAMITHA, S et al.British journal of cancer. 2005, Vol 93, Num 6, pp 647-651, issn 0007-0920, 5 p.Article